Connect with us


Pharma Giant Might Sell Eyecare Division




A turnaround isn’t progressing as quickly as expected.

The chairman of Novartis says it’s possible the pharmaceutical company will sell Alcon, its eyecare unit.

A planned turnaround at Alcon isn’t progressing as quickly as Novartis officials had hoped, Reuters reports.

Chairman Joerg Reinhardt told the Switzerland-based publication SonntagsZeitung that for the long term, “the question arises as to whether we are the best owner for Alcon.”

Alcon, whose U.S. headquarters are in Texas, makes items including contact care products, ophthalmic pharmaceuticals, dry eye products and ocular vitamins. Novartis took ownership of the company through several deals totaling $51 billion.


Reinhardt said Novartis continues to try to turn the company around. For this quarter, he anticipates Alcon sales being flat, or even down a bit, according to SonntagsZeitung.

According to Reuters, Novartis “has blamed a failure to innovate and inconsistent customer service” for Alcon’s issues.

Read more at Reuters


Crizal® Sapphire™ HR: Invisible Shield of Protection

Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular